Scientific Breakthrough Identifies CD99L2 Gene as Primary Cause of Rare X-Linked Spastic Ataxia

Researchers identify CD99L2 as a cause of spastic ataxia, bridging immunology and neurology to solve a major genetic puzzle in rare movement disorders.

By: AXL Media

Published: Mar 17, 2026, 9:10 AM EDT

Source: Information for this report was sourced from Ruhr University Bochum

Decoding the Genetic Origins of Rare Movement Disorders

The quest to understand the underlying causes of rare neurodegenerative conditions has reached a significant milestone through the efforts of researchers at Ruhr University Bochum and the University of Tübingen. By utilizing high throughput sequencing on a vast patient cohort, the team successfully identified the CD99L2 gene as the source of X linked spastic ataxia. This discovery provides a long awaited answer for patients suffering from combined symptoms of coordination loss and spastic paralysis, conditions that have historically eluded precise genetic diagnosis despite modern technological advancements.

Bridging the Gap Between Immunology and Neurology

Until this recent breakthrough, the CD99L2 gene was categorized almost exclusively for its functions within the human immune system. The research led by Dr. Jonasz Weber and Dr. Tobias Haack challenged this conventional classification by demonstrating the gene's previously unknown role within the central nervous system. Through a combination of genome wide analysis and cellular biology, the scientists proved that CD99L2 is not just a secondary actor but a fundamental component in maintaining the integrity of neuronal signal pathways, marking a shift in how researchers view multi functional proteins.

Molecular Interaction with Known Disease Proteins

The functional characterization of the CD99L2 protein revealed that it serves as an essential activating partner for CAPN1, a calcium dependent protease already established as a factor in hereditary spastic paraplegia. According to Dr. Weber, pathogenic variants of the gene disrupt the production of the CD99L2 protein, which in turn prevents its necessary interaction with CAPN1. This failure in protein synergy leads to the specific disruption of synaptic processes, creating a ripple effect of dysregulation that results in the debilitating physical symptoms observed in spastic ataxia patients.